2019
DOI: 10.1080/19336896.2019.1631680
|View full text |Cite
|
Sign up to set email alerts
|

Clinicopathological findings of an MM2-cortical-type sporadic Creutzfeldt-Jakob disease patient with cortical blindness during a course of glaucoma and age-related macular degeneration

Abstract: Here, we report an autopsy-verified patient with MM2-coritical-type sporadic Creutzfeldt-Jakob disease (MM2C-type sCJD) presenting cortical blindness during a course of glaucoma and age-related macular degeneration, and focus on the difficulties involved in early clinical diagnosis. An 83-year-old man was admitted to our hospital 15 months after the onset of cortical blindness, and 9 months after the onset of progressive dementia. Neurological examination revealed dementia, frontal signs, visual disturbance, d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
5

Relationship

3
2

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 27 publications
0
4
0
Order By: Relevance
“…The rarity, rapidity, and clinical heterogeneity of prion disease affects study enrolment and the ability to measure treatment outcomes [34]. Since V180I gCJD is a gradually progressing prion disease [6], we believe that this phenotype may become a potential target of clinical therapeutic trials for prion disease as well as MM2-cortical-type of sCJD [35].Therefore, in the setting of clinical trials, a good understanding of the clinicopathological characteristics of a long-term survivor of V180I gCJD is required.…”
Section: Discussionmentioning
confidence: 99%
“…The rarity, rapidity, and clinical heterogeneity of prion disease affects study enrolment and the ability to measure treatment outcomes [34]. Since V180I gCJD is a gradually progressing prion disease [6], we believe that this phenotype may become a potential target of clinical therapeutic trials for prion disease as well as MM2-cortical-type of sCJD [35].Therefore, in the setting of clinical trials, a good understanding of the clinicopathological characteristics of a long-term survivor of V180I gCJD is required.…”
Section: Discussionmentioning
confidence: 99%
“…All patients were confirmed by genetic analysis to have homozygosity for methionine at codon 129 and no prion protein gene mutation. Two patients in the MM2c-sCJD group, one of whom we previously reported [10], and three patients in the MM1-sCJD group, underwent autopsy.…”
Section: Resultsmentioning
confidence: 99%
“…To confirm the type of PrP res , brain homogenates were analysed by Western blotting using the 3F4 antibody as well as type 1 and type 2 PrP Sc -specific antibodies [10]. Histopathological analyses of the brains of patients with MM2c-sCJD revealed spongiform changes comprised of large confluent vacuoles, and perivascular-and rough plaque-type PrP Sc deposition in the cerebral cortices with preserved inferior olivary nuclei [10]. Spongiform changes with small vacuoles and synaptic-type PrP Sc deposition in the cerebral cortices were identified in the brains of patients with MM1-sCJD.…”
Section: Resultsmentioning
confidence: 99%
“…The frequency of MM2Ctype sCJD is reportedly 2.0% and 6.7% in Caucasian and Japanese sCJD populations, respectively [1]. The average disease duration of MM2C-type sCJD is 15.7--20.6 months [1][2][3]; however, long-term survivors (more than 3 years) have also been reported [4,5]. The implementation of appropriate care for dysphagia is an important factor that enables long-term survival in patients with MM2C-type sCJD [5], and genetic CJD with V180I mutation in PRNP (V180I gCJD) [6].…”
Section: Introductionmentioning
confidence: 99%